Quarterly Results, Awards, Positive Trial Data, and New Board Members Support Optimism for Healthcare - Research Report on

Quarterly Results, Awards, Positive Trial Data, and New Board Members Support  Optimism for Healthcare - Research Report on Allergan, Cubist, Forest, Isis                          Pharmaceuticals, and Amarin  PR Newswire  NEW YORK, July 5, 2013  NEW YORK, July 5, 2013 /PRNewswire/ --  Editor Note: For more information about this release, please scroll to bottom.  Today, Wall Street Reports announced new research reports highlighting Allergan Inc. (NYSE: AGN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Forest Laboratories Inc. (NYSE: FRX), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.  Allergan Inc. Research Report  On June 28, 2013, Allergan Inc. (Allergan) announced that the Company will release its Q2 2013 results on Wednesday, July 31, 2013. The release will be discussed by David Pyott, Chairman of the Board and Chief Executive Officer, along with Jeff Edwards, Executive Vice President of Finance and Business Development and Chief Financial Officer of Allergan. The Company further informed that investors may access a live webcast of the release at Allergan's website, beginning at 8:00 a.m. PT. A replay of the same will also be available at the Company's website for one week after the conclusion of the live call. The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/1c25_AGN]  --  Cubist Pharmaceuticals Inc. Research Report  On June 28, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that Michael W. Bonney, CEO of Cubist, was named among the winners of the Ernst & Young Entrepreneur Of The Year 2013 Award New England, in the Life Sciences category. Bonney commented, "I am honored to be recognized as one of the Ernst & Young Entrepreneur Of The Year Award New England winners. It is truly humbling to be in the company of such great leaders across the region." He continued, "The award is a reflection of all of Cubist's employees who bring passion and dedication to our mission of transforming patients' lives. The award also recognizes Cubist's dedication to the New England area, supporting local communities through middle and high school science, technology, engineering and math (STEM) education programs. Our support of STEM education is an integral part of Cubist's corporate culture of which I am personally proud." The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/92f0_CBST]  --  Forest Laboratories Inc. Research Report  On June 27, 2013, Forest Laboratories Inc. (Forest) reported positive top line results from its eight-week pivotal Phase III clinical trial, conducted to evaluate the efficacy and safety of investigational fixed dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension. Marco Taglietti, MD, Senior Vice President of Research and Development and President at Forest Research Institute, stated, "These Phase III results in patients with Stage 1 or Stage 2 hypertension are exciting and demonstrate the potential benefits of this novel FDC -- a first-in-class beta blocker/ARB combination." Taglietti added, "We are very pleased with these results which demonstrate the efficacy and safety profile of this combination and support the potential use of the nebivolol/valsartan FDC as a new treatment option for patients with hypertension who need dual therapy to reach their blood pressure goals." Forest also reported that based on the positive outcome of the trial, the Company intends to submit a regulatory filing with the US Food and Drug Administration during Q1 2014. The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/e121_FRX]  --  Isis Pharmaceuticals, Inc. Research Report  On June 25, 2013, Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals) announced that Breaux Castleman has joined its Board of Directors. Stanley T. Crooke, M.D., Ph.D., Chairman and CEO of Isis said, "We are very pleased to have Breaux join our Board. Breaux has held executive positions in some of the nation's leading managed care provider organizations and has been a pioneer in creating innovative solutions to deliver value in the healthcare sector." Crooke continued, "Breaux' leadership and sound business judgment will be valuable to Isis as we continue to successfully implement our business strategy and evaluate opportunities within our pipeline to retain some of our drugs to later stages in development; thereby retaining a larger portion of the commercial upside of these drugs." The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/f5f5_ISIS]  --  Amarin Corporation plc Research Report  On June 21, 2013, Amarin Corporation plc (Amarin) announced positive results from the Phase I clinical trial that compared the bioavailability of components from a fixed-dose combination of Vascepa (icosapent ethyl) and rosuvastatin (AMR-102), to concomitant administration of the two agents independently, and to rosuvastatin alone. Joseph Zakrzewski, Chairman and CEO of Amarin, stated, "The encouraging results of this pharmacokinetic study represent a crucial step in the plan to solidify a fixed-dose formulation of Vascepa capsules with statins." Amarin reported that the results of multiple-dose study to assess the AMR-102 in 48 volunteers proved promising and was well-tolerated. The Company also reported that under its ANCHOR trial, Vascepa showed robust reductions in TGs and a broad range of other lipid parameters on top of optimized statin therapy, including atorvastatin, simvastatin, and rosuvastatin. Zakrzewski continued, "These claims from the ANCHOR fixed-dose formulation, along with other recently allowed and granted patents that cover a fixed dose combination product from the MARINE trial give Amarin a strong IP position for AMR-102." The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/79f9_AMRN]  ----  EDITOR NOTES:  1.This is not company news. We are an independent source and our views do     not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts     basis and reviewed by a CFA. However, we are only human and are prone to     make mistakes. If you notice any errors or omissions, please notify us     below. 3.This information is submitted as a net-positive to companies mentioned, to     increase awareness for mentioned companies to our subscriber base and the     investing public. 4.If you wish to have your company covered in more detail by our team, or     wish to learn more about our services, please contact us at     pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at     compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your     company? Send us a full investors' package to     research@EquityNewsNetwork.com for consideration.  COMPLIANCE PROCEDURE  Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.  NOT FINANCIAL ADVICE  Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.  NO WARRANTY OR LIABILITY ASSUMED  Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.  SOURCE Wall Street Reports  Contact: WSReports.com Phone #: +1-310-496-8071 (North America)  
Press spacebar to pause and continue. Press esc to stop.